Please login to the form below

Not currently logged in
Email:
Password:

Dacogen

This page shows the latest Dacogen news and features for those working in and with pharma, biotech and healthcare.

Otsuka to buy cancer biopharma Astex

Otsuka to buy cancer biopharma Astex

Otsuka to buy cancer biopharma Astex. Takes control of company behind Dacogen in $886m deal. ... Astex' lead product is Dacogen (decitabine), which is approved for the treatment of myelodysplastic syndromes and for acute myeloid leukaemia (AML) in

Latest news

  • European approvals for J&J cancer treatments

    European approvals for J&J cancer treatments. EC passes new Dacogen indications and backs subcutaneous Velcade. ... The European Commission has approved an extra indication for Johnson &Johnson's cancer drug Dacogen as well as a subcutaneous version of

  • Developing drugs to conquer cancer Developing drugs to conquer cancer

    Eisai reported new results on eribulin (Halaven) in early-stage breast cancer and decitabine (Dacogen) in acute myeloid leukemia, as well as new data on several phase I agents under investigation

  • Cancer data presented at ASCO

    Elsewhere, Eisai presented data concerning a phase III study of DNA methylation inhibitor Dacogen (decitabine) for injection in acute myeloid leukaemia (AML).

  • J&J positive about pipeline

    this month; and Dacogen (decitabine), currently sold as a treatment for myelodysplastic syndromes, for the new indication of acute myeloid leukaemia.

  • SuperGen and Astex to merge

    It plans to leverage a revenue stream from its product Dacogen, marketed in North America by Eisai and in the rest of the world by Johnson &Johnson.

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2013 Pharma deals during September 2013

    Astex' lead product is Dacogen (decitabine) for myelodysplastic syndromes (MDS). It was also recently approved for acute myeloid leukaemia (AML) in patients over 65 years of age in Europe.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics